Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
about
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancerThe predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkersEGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancerUpdate of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapyHeterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibodyCurrent approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patientsChemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions.Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.Persistent low expression of hZip1 in mucinous carcinomas of the ovary, colon, stomach and lungMutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer.Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials.Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP methodPersonalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: a future opportunity?Personalized treatment for patients with colorectal cancer: role of biomarkers.Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer.Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients.Molecular Biomarkers for the Evaluation of Colorectal Cancer.
P2860
Q26796348-840A1C18-538C-404C-96B0-FF335741D20BQ27027648-B0613CD3-36E2-486B-AC05-92F4D5B69F98Q27852988-B3B95BAB-8193-46E1-B9EA-6F1D233453E7Q28087333-13EE87A6-5D53-4E6C-9A6A-D0FEE714468EQ33276007-422A1BD9-6923-4285-9934-B0092AF07D3AQ33631430-F51B522C-EDF4-4861-8B3F-3CDD953A0D27Q33710179-83070219-C5DC-423A-8661-263A38FB3638Q33858231-D7B759C5-39B4-4ADD-A48C-7484836828F9Q33861210-C4F85280-99C2-469B-B18E-24DFF3B819CCQ34654543-C9FAB723-125E-4BFC-8B60-C66BAA3EB88DQ35674206-F359B736-6F7C-4394-9087-34C594963997Q35776312-E0D81C2C-0F4C-47C4-99AD-D735176AC772Q35944622-11795DB0-B4FB-41DC-B6C9-1CCB755CCE42Q36006605-2378E76A-1572-4732-9AC6-51CF543015C5Q36074183-C91EA35F-C71A-4B0D-879B-D9F4E0D9E41AQ38186790-0772840D-942D-4C35-883C-025C5480B47DQ38390834-3CE2D8F9-95DE-46B4-8521-54CE07F73734Q38390840-E854421E-C3A0-499B-A1C1-C66B27DAD294Q38805790-E484A1C0-804D-4CB3-9936-A0CD0D891050Q40341349-BF0E1999-03DF-468B-A1A2-8A4F75B511C6Q40686537-0A1EB2AE-907D-4076-A73C-A40430343C34Q41410508-BAF566A1-74C8-41C8-BEC0-FC8173C01F27Q49996562-5962CD77-D8F7-40C7-886C-A06CE0B079D2Q52794464-7861F59E-A873-4DB1-8089-7397FEF519D4
P2860
Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Promising biomarkers for predi ...... tic review with meta-analysis.
@en
type
label
Promising biomarkers for predi ...... tic review with meta-analysis.
@en
prefLabel
Promising biomarkers for predi ...... tic review with meta-analysis.
@en
P2093
P2860
P921
P356
P1476
Promising biomarkers for predi ...... tic review with meta-analysis.
@en
P2093
Da-Yong Zheng
Jin-Ling Tang
Jin-Zhang Chen
Meng-Yang Di
Xin-Yin Wu
Ya-Fang Huang
Zu-Yao Yang
P2860
P304
P356
10.1002/IJC.28153
P577
2013-07-13T00:00:00Z